Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 10/20 | 0.45 |
| ▸ | LOX | P28300 | 5/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.34 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.33 |
| ▸ | UTRN | P46939 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30500402 | 0.98 | LOXL2 (0.44) | LOXL2LOXHCRTR1HCRTR2GRM2 | |
| SCHEMBL13164105 | 0.86 | LOXL2 (0.61) | LOXL2LOXHCRTR1HCRTR2LOXL3 | |
| Hydrochloric Acid SCHEMBL25210344 | 0.85 | LOXL2 (0.59) | LOXL2LOXHCRTR1HCRTR2LOXL3 | |
| SCHEMBL4536253 | 0.79 | HCRTR1 (0.40) | LOXL2LOXHCRTR1HCRTR2GRM2 | |
| SCHEMBL14925194 | 0.79 | HCRTR1 (0.40) | LOXL2LOXHCRTR1HCRTR2GRM2 | |
| SCHEMBL18083206 | 0.79 | NOS3 (0.47) | LOXL2LOXHCRTR1HCRTR2GRM2 | |
| SCHEMBL1437199 | 0.79 | RECQL (0.47) | LOXL2LOXHCRTR1HCRTR2GRM2 | |
| SCHEMBL30329140 | 0.79 | RECQL (0.47) | LOXL2LOXHCRTR1HCRTR2GRM2 | |
| SCHEMBL17000198 | 0.77 | LOXL2 (0.41) | LOXL2LOXHCRTR1HCRTR2GRM2 | |
| SCHEMBL28806544 | 0.77 | HCRTR1 (0.38) | LOXL2LOXHCRTR1HCRTR2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336571-A1 | NOVEL CYCLOPROPYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2024-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336571-A1 | NOVEL CYCLOPROPYL COMPOUNDS | C1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR1 | LOXL2 4525/4885LOX 4419/4885HCRTR1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.